Another painful day in the bio-trading world. To hopefully ease some of the ache I have started a position in ZLCS ahead of phase 2 data for their analgesic development compound, Z160. Volume has been growing since the start of the month, with a favourable article in Seeking Alpha having been published on August 1. Hopefully interest will grow as the data draws near (expected early in Q4). I am in at $0.71.